Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 405 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
Patents for C07D 405 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom (69,397)
09/2005
09/22/2005WO2005087236A1 Novel m3 muscarinic acetylcholine receptor antagonists
09/22/2005WO2005087227A1 Arylalkylamino-substituted quinazoline analogues
09/22/2005WO2005087215A1 Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
09/22/2005WO2005086895A2 Ion channel modulators
09/22/2005WO2005086656A2 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
09/22/2005WO2005074654A3 Methods to manufacture 1,3-dioxolane nucleosides
09/22/2005WO2005072681A3 Vanilloid receptor ligands and their use in treatments of inflammatory and neurotic pain.
09/22/2005US20050209470 Diastereoselective epoxidation of allylically substituted alkenes using metalloporphyrin catalysts
09/22/2005US20050209456 Vascular endothelial growth factor; tyrosine kinase inhibitor; angiogenesis inhibitor; anticancer agents
09/22/2005US20050209437 Polymer compounds containing oxetane and maleimide functionality
09/22/2005US20050209302 Glycogen synthase kinase (GSK-3) inhibitors; diabetes, neurodegenerative diseases, stroke, neurotraumatic injuries and bipolar disorders; 5-acetyl-3-[3-(methoxycarbonylpropylamino)-(benzo-[1.3]dioxyo-5-yl)-methylidene]-2-indolinone for example
09/22/2005US20050209287 3-thio-4,5-disubstituted-4H-1,2,4-triazoles; Inhibiting RNase H activity, and RNA dependent DNA polymerase (RDDP) activity of HIV reverse transcriptase; 4-benzyl-3-(benzylthio)-5-(2-furyl)-4H-1,2,4-triazole for example; retrovirus-associated cancer; drug screeening
09/22/2005US20050209285 Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs
09/22/2005US20050209282 Inhibitors of voltage-gated sodium channels; acute, chronic, neuropathic, or inflammatory pain such as femur cancer pain; non-malignant chronic bone pain; rheumatoid arthritis; osteoarthritis; spinal stenosis; neuropathic low back pain; neuropathic low back pain; myofascial pain syndrome; fibromyalgia
09/22/2005US20050209278 Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
09/22/2005US20050209274 Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
09/22/2005US20050209273 Neuroprotectants, analgesics or anticonvulsants
09/22/2005US20050209260 Purinergic receptor antagonists; genitourinary and pain-related diseases; for example, 5-(2-isopropyl-4,5-dimethoxybenzyl)-pyrimidine-2,4-diamine
09/22/2005US20050209252 Using an indazole compound
09/22/2005US20050209249 Use as antidiabetic agents, treating hyperglycemia, syndrome X, hyperinsulinemia, obesity, atherosclerosis; (3S, 5S)-4-([5-(Thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-sulfamoyl)-benzoic acid for example
09/22/2005US20050209247 Lactate salt of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; improved water solubility and physicochemical properties (e.g., stability, hygroscopicity, crystallinity, and compactibility); vascular endothelial growth factor receptor tyrosine kinase inhibitors
09/22/2005US20050209245 Process for preparing N-aryl-piperazine derivatives
09/22/2005US20050209232 Useful for treating inflammatory, immunological, and integrin-mediated disorders such as inflammatory bowel disease; 2-(3,3-Diisopropyl-ureido)-3-[4-(5-methoxy-2-methyl-3-oxo-2,3-dihydro-pyridazin-4-yl)-phenyl]-propionic acid for example
09/22/2005US20050209231 In embryonic stem cells in vitro and in vivo; cardiomyopathy; 2,6-diaminopyrimidine compounds
09/22/2005US20050209230 2,4-Pyrimidinediamine compounds and their uses
09/22/2005US20050209224 N4-(4H-5-pyrid[1,4]oxazin-6-yl)-2,4-pyrimidinediamine derivatives; for treating rheumatoid arthritis
09/22/2005US20050209223 N-(p-(substituted 1,2,3-triazol-1-yl)phenyl) derivatives of cycloazaalkanes; particularly useful for treating methicillin-resistant Staphylococcus aureas infections
09/22/2005US20050209213 Quinoline compound
09/22/2005US20050209165 Hypercholesterolemia, cholesterol-associated benign and malignant tumors; hyperlipidemia, arteriosclerosis, and sitosterolemia; 6) (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(2',3',4'-trimethoxybiphenyl-4-yl)azetidin-2-one
09/22/2005US20050209162 Methods for monitoring IL-18
09/22/2005US20050209106 Herbicides; selectively controlling broad-leaved weeds and weed grasses in crops of useful plants; 6-ethyl-4-(4-trifluoromethyl-1H-1-pyrazolyl)-2-(2-trifluoromethylpyridin-4-yloxy)pyrimidine
09/22/2005US20050208582 Pyrazole compounds and pharmaceutical compositions comprising the compound
09/22/2005CA2560098A1 2-aminoquinazoline derivative
09/22/2005CA2559143A1 Novel cycloalkyl-containing 5-acylindolinones, their preparation and their use as pharmaceutical products
09/22/2005CA2559139A1 Novel alkyl-containing 5-acylindolinones, their preparation and their use as pharmaceutical products
09/22/2005CA2559115A1 Novel aryl-containing 5-acylindolinones, the production thereof and their use as medicaments
09/22/2005CA2558249A1 Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
09/22/2005CA2558224A1 Ion channel modulators
09/22/2005CA2558036A1 Substituted hydroxyethylamine aspartyl protease inhibitors
09/22/2005CA2558034A1 Substituted hydroxyethylamine aspartyl protease inhibitors
09/22/2005CA2557904A1 Hiv integrase inhibitors
09/22/2005CA2557648A1 Ion channel modulators
09/22/2005CA2557527A1 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
09/22/2005CA2555867A1 Arylalkylamino-substituted quinazoline analogues
09/21/2005EP1577296A1 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their use
09/21/2005EP1577295A1 Process for preparing 2-oxo-1-pyrrolidine derivatives as intermediates
09/21/2005EP1577288A1 Selective estrogen receptor modulators
09/21/2005EP1576954A1 Preferential inhibition of release of pro-inflammatory cytokines
09/21/2005EP1575951A1 Heterocyclic compounds, methods of making them and their use in therapy
09/21/2005EP1575943A1 3-cyano-quinoline derivatives
09/21/2005EP1575940A1 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer
09/21/2005EP1575919A1 Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist
09/21/2005EP1575918A2 Substituted biaryl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators
09/21/2005EP1339694B1 Substituted 2-phenylaminoimidazoline phenyl ketone derivatives as ip antagonists
09/21/2005EP1299382B1 Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives
09/21/2005EP1265862B1 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
09/21/2005CN1671717A Azole derivatives as antifungal agents
09/21/2005CN1671711A Calcitonin gene related peptide receptor antagonists
09/21/2005CN1671700A Substituted alkylamine derivatives and methods of use
09/21/2005CN1671698A 4-trifluoromethylpyrazolyl substituted pyridines and pyrimidines
09/21/2005CN1671695A Pyrrolidinedione substituted piperidine-phthalazones as PDE4 inhibitors
09/21/2005CN1671684A Novel benzodioxoles
09/21/2005CN1671671A 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) im
09/21/2005CN1671667A Quinoline derivatives and their use as mycobacterial inhibitors
09/21/2005CN1671662A Piperidine derivative, process for producing the same, and use
09/21/2005CN1671386A Substituted anilinic piperidines as MCH selective antagonists
09/21/2005CN1671379A Hydrazonopyrazole derivatives and their use as therapeutics
09/21/2005CN1671373A Compounds useful for the inhibition of ALDH
09/21/2005CN1219780C Heterocyclic compounds binding chemotactic factor receptor
09/21/2005CN1219768C Quinoline derivatives as inhibitors of MEK enzymes
09/21/2005CN1219763C Substituted indole mannich bases
09/21/2005CN1219556C The use of 4-H-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation
09/21/2005CN1219510C Benzimidazole derivatives as modulators of IgE
09/20/2005US6946483 Aminoalkenylbenzoyl-benzofuran or benzothiophene, method for preparing same and compositions containing same
09/20/2005US6946481 Endothelin antagonists
09/20/2005US6946478 Compounds
09/20/2005US6946471 2-(2,6-Dichlorophenyl)-Diarylimidazoles
09/20/2005US6946462 N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents
09/20/2005US6946460 such as cis-4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]-N-methyl-N-(3-phenyl-2(E)-propenyl)-benzenemethanamine;
09/20/2005CA2285119C Retroviral protease inhibiting compounds
09/20/2005CA2211668C Substituted heterocyclic compounds, preparation method therefor and pharmaceutical compositions containing the same
09/20/2005CA2137243C Process for the production of n-.beta.-hydroxyalkyl-tri-n-carboxyalkyl -1,4,7,10-tetraazacyclododecane and n-.beta.-hydroxyalkyl-tri-n-carboxyalkyl-1,4,8,11- tetraazacyclotetradecane derivatives and their metal compllexes
09/20/2005CA2084582C Process for the production of mono-n-substituted tetraaza macrocycles
09/15/2005WO2005085275A1 Inhibitors of hepatitis c virus ns3 protease
09/15/2005WO2005085237A1 Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
09/15/2005WO2005085236A2 Caspase inhibitors and uses thereof
09/15/2005WO2005085234A2 Bycyclic anthranilamide derivatives useful as insecticides
09/15/2005WO2005085225A1 Novel hydroxy-6-heteroarylphenanthridines and their use as pde4 inhibitors
09/15/2005WO2005085214A1 Diaryl-substituted five-membered heterocycle derivative
09/15/2005WO2005085212A1 Substituted pyrimidine derivative
09/15/2005WO2005085209A1 Basic amine compound and use thereof
09/15/2005WO2005085201A1 Novel cyclic compound having 4-pyridylalkylthio group having (un)substituted amino introduced therein
09/15/2005WO2005085200A1 Pyridone derivative
09/15/2005WO2005085198A2 Amino cyclopropane carboxamide derivatives as bradykinin antagonists
09/15/2005WO2005085194A2 Indole-2-carboxylic acid hydrazides as glycogen phosphorylase inhibitors
09/15/2005WO2005085177A2 Biaryl amino acids and their use in dna binding oligomers
09/15/2005WO2005067502A3 Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity
09/15/2005WO2005055940A3 Novel m3 muscarinic acetylcholine receptor antagonists
09/15/2005WO2005054430A3 Hepatitis c virus inhibitors
09/15/2005WO2005049604A3 Antithrombotic aromatic ethers
1 ... 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 ... 694